key: cord-0879458-b6d2yjlg authors: Li, Jingwen; Long, Xi; Zhang, Qing; Fang, Xi; Luo, Huiling; Fang, Fang; Lv, Xuefei; Zhang, Dandan; Sun, Yu; Li, Na; Hu, Shaoping; Li, Jinghong; Xiong, Nian; Lin, Zhicheng title: Pearson’s patterns correlational of clinical risks at admissions with hospitalization outcomes during initial COVID-19 outbreak date: 2022-05-18 journal: iScience DOI: 10.1016/j.isci.2022.104415 sha: 703d0487c05304fe8638eaa2428a2ad75f4d9751 doc_id: 879458 cord_uid: b6d2yjlg COVID-19 outbreaks have crushed our healthcare systems, which requires clinical guidance for the healthcare following the outbreaks. We conducted retrospective cohort studies with Pearson’s pattern-based analysis of clinical parameters of 248 hospitalized patients with COVID-19. We found that dysregulated neutrophil densities were correlated with hospitalization duration before death (P=0.000066, r=-0.45 for % neutrophil; P=0.0001, r=-0.47 for neutrophil count). As such, high neutrophil densities were associated with mortality (P= 4.23 x 10-31 for % neutrophil; P= 4.14 x 10-27 for neutrophil count). These findings were further illustrated by a representative “second week crash” pattern and validated by an independent cohort (P= 5.98 x 10-11 for % neutrophil; P= 1.65 x 10-7 for neutrophil count). By contrast, low aspartate aminotransferase (AST) or lactate dehydrogenase (LDH) levels were correlated with quick recovery (P <0.00005). Collectively, these correlational at-admission findings may provide healthcare guidance for patients with COVID-19 in the absence of targeted therapy. The widespread COVID-19 has caused hundred million infections, more than 2% of them dead and crushed our healthcare capacity in many regions (Patrucco et al., 2021; Rubin, 2020) . This pandemic has demonstrated the need to identify clinical risk factors that could foresee hospital outcomes for patients with novel infectious diseases such as COVID-19. This became particularly true in the absence of effective therapy, depending only on supportive care, oxygen therapy, non-invasive mechanical ventilation and invasive mechanical ventilation (Alhumaid et al., 2020) . Many studies have identified clinical characteristics as risk factors associated with severe COVID-19. These factors include aging, male gender, comorbidities, high D-dimer, C-reactive protein (CRP), lactate dehydrogenase (LDH), and white blood cells (WBCs) levels and low lymphocyte levels (Ou et al., 2020; Parohan et al., 2020) . No comprehensive patterns/correlational study has been carried. The purpose of this retrospective cohort study, as outlined in Figure 1 , was to , by Pearson's correlation, comprehensively delineate the prognostic markers for hospitalization duration and mortality by correlating disease history, vital signs and laboratory (27 in toto) parameters for initial COVID-19 patients when both healthcare workers and patients were in panic. We studied two independent cohorts, each with a surviving group versus a deceased group of the COVID-19 patients. We found laboratory results from the blood could serve as J o u r n a l P r e -p r o o f prognostic markers for hospital outcomes. We also did an extensive database search of ongoing clinical trials for marker-related therapies. The retrospective cohort study has two groups, 174 patients survived and were discharged from hospital as the surviving group and 74 patients died as the deceased group. All patients were confirmed with COVID-19 and were hospitalized at Wuhan Red Cross Hospital (WRCH) in Wuhan, China. Most of examined clinical characteristics including age, gender, signs and symptoms, laboratory results at admission are shown in Table 1a . The median age of the deceased group was 20 years older than the surviving group. Among 74 deceased patients, 81% were over 60 years old and males accounted for the majority (65%). The two groups had similar symptoms of fever and cough at admission for which were the most common symptoms among all the patients. For the deceased group, they had significantly higher rate of shortness of breath, fatigue, and myalgia. For the surviving group, they had more gastrointestinal tract symptoms such as nausea, vomiting and diarrhea. Numerous laboratory findings were found significantly different between the surviving group and the deceased group (Table 1b ). The deceased group had higher levels in several parameters, including elevated D-dimer (12.3-fold), CRP (7.5-fold), LDH (2.2-fold). The deceased group had elevated total WBC count (1.8-fold), elevated neutrophil percentage J o u r n a l P r e -p r o o f (1.49-fold) , and decreased lymphocyte percentages (0.2-fold). All of the above parameters were statistically significant (p<0.0001) between the surviving and deceased groups. The abnormalities of these parameters are typically seen in severe COVID-19 patients from previous studies (Huang et al., 2020; Wu et al., 2020; Zhou et al., 2020) . Therefore, the laboratory parameters confirmed that indeed the surviving group patients had mild disease and the deceased group patients had severe disease, respectively. A total of 32 clinical parameters were retrieved from the medical records (Table 1) . Indexing powers for three aspects including surviving versus deceased, hospitalization duration before discharge for the survivors and hospitalization duration before death for the deseased, were examined. For the surviving group, 4 of the 32 parameters displayed concentration-or abundance-dependent and positive associations with hospital days before discharge. The 4 parameters are aspartate aminotransferase (AST), LDH, ALT and more than one sign or symptom ( Figure 2 ). Furthermore, LDH displayed gender-specificity: the correlation was much stronger in females (p=0.00005) than males (p=0.032 which failed multiple-testing). LDH was not a covariant of the other three parameters (p<0.0001) but the other three were covariant with each other. The remaining 28 parameters were not covariant with hospital days J o u r n a l P r e -p r o o f 6 before discharge. Other parameters such as age, D-dimer, neutrophil percentage, and lymphocyte count had correlational tendencies but they were not significant (data not shown). For the deceased group, 5 of the 32 parameters were concentration-dependently correlated with hospitalization duration before death. The top four specific parameters were neutrophil count, neutrophil percentage, and lymphocyte percentage (all p<0.0005) ( Figure 3a -c). The fifth one was prothrombin time (PT) for which showed a significant correlation only in males (p=0.0017) (Figure 3d ). Lymphocyte percentage had positive correlation and all others had negative correlations, as shown in Figure 3 . These appeared to be covariant based on similar slopes. Therefore, all of these correlations reached statistical significances. The subset types of WBC, neutrophil count, neutrophil percentage, and lymphocyte percentage were correlated with the hospitalization duration before death. We have also examined neutrophil-to-lymphocyte ratio (NLR) and found no significant correlation (data not shown). One of the clinical features we observed from COVID-19 patients was a portion of patients presented with mild disease, they could be feeling better and then suddenly getting worse around two weeks into the disease course. This is so called "second week crash". It was thought that these patients might have suffered from cytokine storm (Fajgenbaum and June, 2020). We analyzed a case like this to study the time course. Besides J o u r n a l P r e -p r o o f concentration-dependence, time course may allow simultaneous cross-referring among multiple parameters. This patient presented with mild severity at admission but worsened within 2-3 weeks, leading to death within 26 days. A 65-year-old man was chosen with no significant past medical history but fatigue for 3 days, cough and low-grade (37.8 o C) fever for 1 day. The choice of this patient was due to three parts of causes. First of all, his age accounted for the largest proportion of COVID-19 deaths, which was of important clinical significance. Second, he had no other underlying diseases, and the confounding factors and influence of other diseases on our target index could be excluded to the maximum extent. Thirdly, his changes of index were significant and representative, with complete clinical data (i.e., CT images and clinical symptoms), which was more convincing. He was hospitalized on illness day 3 (iDay 3). His clinical course from iDays 4 to iDay12 was relatively stable except intermittent fevers, nonproductive cough, abdominal discomfort and diarrhea; however, he developed progressive leukocytosis with predominant neutrophils and lymphocytopenia ( Figure 4a ). He had elevated CRP through the disease course. His PT was mildly elevated and went up by the last days; his AST and ALT were within normal limits until the last 2-3 days (no LDH information was available). Chest CT showed progressive lung damage from iDay 6 ( Figure 4b ) and his reverse transcriptase-polymerase chain reaction (RT-PCR) results came back positive on iDay 24. On iDay 28, he had multiple-organ failure and secondary bacterial infection. He had cardiopulmonary arrest and died on iDay 29. As shown in Figure 4 , the best correlations were between CT or RT-PCR findings of J o u r n a l P r e -p r o o f disease severity and the WBC subset cells' densities, as the disease progressed. Once the lung damage detected, lymphocyte count started dropping on the same day and never recovered. His neutrophil count represented almost all of his WBCs' counts after iDay 13 when his lungs were progressively damaged ( Figure 4b ) till iDay 25. This patient had very high neutrophils but very low lymphocytes. This patient failed to clear the SARS-CoV-2 virus with persistent positive RT-PCR. The platelet count was a negative control. Various therapies available at that time were given (not listed here) without success. To study the correlational findings of WBC, neutrophil count, neutrophil percentage, and lymphocyte percentage with the mortality, group-based distributions were further evaluated to see whether the neutrophil abundance might be associated with the mortality. Based on the results in Figures 3 and 4 , the top two parameters were considered: neutrophil percentage and neutrophil count. We compared the surviving group and the deceased group. Both neutrophil percentage and neutrophil count affirmed visually differential distributions between the two groups ( Figure 5 , top panels). To validate this finding, we registered another cohort of 143 patients, including 119 survivors and 24 death cases. The data were analyzed separately and the results were shown in Figure 5 lower panels. Data from both cohorts were consistent with each other, confirming the dysregulated neutrophil densities were correlated with hospitalization duration before death. J o u r n a l P r e -p r o o f We carried out the first Pearson's correlation (quantitative) study of 27 clinical parameters to clarify prognostic markers for hospital outcomes including mortality in initial Chinese COVID-19 patients. Severe COVID-19 cases involve systemic damage and multiple-organ failure with high mortality rate. We postulated that there were some systemic parameters that we could delineate from the retrospective cohort study database. We found the dysregulated neutrophil densities were correlated with hospitalization duration before death. Surged neutrophil abundance was a poor prognostic marker for severe COVID-19 patients, supporting the findings from previous qualitative studies (reviewed by (Reusch et al., 2021) . In general, the clinical parameters that serve as prognostic markers are determined by their concentration-dependent correlations with patients' outcome. Interestingly, different sets of measures index different aspects of the prognosis, including surviving or not (indexing); if surviving, how long the recovery will take (length of hospital stays); if not, how long the patient will remain critically ill (hospitalization duration before death). The correlation directions of these parameters are then cross verified in various settings for consistency. For example, increased neutrophil percentage is correlated with shorter hospitalization duration before death. It's also positively correlated with longer hospital stay for the surviving group Many clinical trials are targeting neutrophils among other related cell type in COVID-19. As of middle September 2021, more than ten thousand clinical trials on COVID-19 were downloaded from the three major registries and inter-registry duplicates were removed. As a result, four thousands of them were interventional in search for effective treatments, including two thousands from clinicaltrials.gov, three hundred from EU Clinical Trials Register and one thousand from the WHO registry. Two hundred and one (5%) of them were designated to use drugs including 19 those could target 15 different molecules expressed by neutrophils in more than hundred thousand patients, located in more than 46 countries (Table 2 ). Those drugs carried at least six mechanisms, including attenuating neutrophil infiltration . Another JAK inhibitor, baricitinib, has also been shown able to help and prevent this disease from progression to severe forms and reduce mortality, partly by restoring normal-abundance neutrophils (Bronte et al., 2020; Kalil et al., 2020; Marconi et al., 2021) (Table 2) (Table 2) . From other clinical trials, more positive results are anticipated, as for fostamatinib which blocks neutrophil activation (Strich et al., 2021) . Such information suggests that our findings in Chinese patients may apply to other ethnicities, which warrants additional Pearson's analysis. This study has several limitations such as lack of ethnicity comparison. Stages of the disease at admission and comorbidity were not included in the correlations, and correlations alone do not demonstrate causality. Longitudinal study involved N of 1. Cellular morphology, low vs normal abundance subpopulation (neutrophil subsets), was not examined. In general, the mechanism for the neutrophil surges was not explored for this retrospective study. Furthermore, unlike an interventional clinical trial, this retrospective study by design was set to test a correlation between two continuous variables. Therefore, such correlation did not demonstrate a causal effect. The authors declare no competing interests. (a) A different patient was admitted on iDay 3 and passed away on iDay 29. His lung damage started on iDay 6 and RT-PCR was able to detect SARS-CoV-2 RNA on iDay 24 (negative on iDays 5 and 9); cells counted were lymphocyte (red, x 10 7 /L), platelet (blue, x 10 9 /L), white blood cells (WBCs, black, x10 8 /L) and neutrophil (green, x 10 8 /L). (b) Chest CT scan imaging of his disease progression in our time points: iDays 3 (a-c), 6 (d-f), 9 (g-i), and 13 (j-l); blue arrows in d-f: new ground-glass opacities in the left lower lobe; purple arrows in g-i: original lesion enlarged; green arrows in j-l: more severe, progressive bilateral ground-glass opacities involving the subpleural area. Red boxes, disease progression in the right lung. Figure 5 . Differential distribution of two mortality-correlated neutrophil measures between surviving (green) and death (red) groups. Upper panels, study cohort; lower panels, validation cohort; p values from two-tailed t-tests of averages. Detailed methods are provided in the online version of this paper and include the following: • KEY RESOURCES TABLE Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Zhicheng Lin (zhicheng_lin@hms.harvard.edu). This study did not generate new unique reagents. Anonymous human participant research data used in this report was designated for this study, and further data sharing is restricted and not publicly available. No formatted data types are detailed in this manuscript. Data requests could be submitted to the lead contact, evaluated by and require an agreement of the Ethics Committee. Summary statistics are already shown in the main Manuscript. Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request. This retrospective, noninterventional study consisted of COVID-19 patients who were admitted to WRCH during the initial outbreak of COVID-19 from January to March of 2020 in Wuhan of China. No selection of subjects was made based on age or gender. The study was performed in accordance with the Declaration of Helsinki and national and institutional standards. The study was approved by the Institutional Review Board, namely, the WRCH Ethics Committee. All patients were tested positive at the time of admission, according to the fifth version guidelines of COVID-19 diagnosis and treatment in China. Study cohort and validation cohort were randomized. The study group consisted of 74 patients who died from COVID-19 and 174 patients who survived COVID-19. All patients were confirmed with COVID-19 by positive RT-PCR for SARS-CoV-2. Outcomes are the length of hospital stay before discharge or before death. The study protocol was approved by the WRCH Ethics Committee. Written informed consent was obtained from study participants for the publication of any potentially identifiable images or data included in this article. A trained team of physicians reviewed and collected clinical and outcomes data from electronic health records at WRCH. All the individual components of the database were recorded and checked separately by two independent physicians. Data were summarized using a standardized database collection form. Information retrieved from the collected data was reviewed and cross-checked for accuracy by two additional trained physicians (N.X. and J.L.). No data were excluded from this study and all de-identified data in associated table and figures are available. Terms "COVID-19", "neutrophil", "drug", "treatment" and "intervention" were used to search three clinical trial databases, the US database (clinicaltrials.gov), the European database (clinicaltrialsregister.eu) and the WHO International Clinical Trials Registry (who.int/trialsearch) for treatments of COVID-19. Trials related to drugs targeting J o u r n a l P r e -p r o o f neutrophils, included those previously reviewed (Németh et al., 2020) , were retrieved and summarized. • QUANTIFICATION AND STATISTICAL ANALYSIS Categorical variables were described as frequency rates and percentages. Data were expressed in mean ± s.e.m. (standard error of the mean), as shown in Table 1 Other measures analyzed included mean arterial pressure, heart rate, fever, breath rate and neutrophil-to-lymphocyte ratio (NLR). Other measures analyzed included mean arterial pressure, heart rate, fever, breath rate and neutrophil-tolymphocyte *Data are median, n (range) or n (%). p values comparing deceased patients and surviving patients were from χ² tests or Fisher's exact tests. p <0.05 was considered statistically significant (in bold); ns, not significant. # Data are median, n (range) or n (%). p values were from χ² tests or Fisher's exact tests. p < 0.05 was considered statistically significant (in bold). J o u r n a l P r e -p r o o f COVID-19's Crushing Effects on Medical Practices, Some of Which Might Not Survive Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial Fostamatinib Inhibits Neutrophils Extracellular Traps Induced by COVID-19 Patient Plasma: A Potential Therapeutic Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease Tocilizumab combined with favipiravir in the treatment of COVID-19: A multicenter trial in a small sample size Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study Recombinant DNA None Software and algorithms SPSS IBM